HCPLive Network

Single-Question Patient Survey Can Accurately Assess Low Back Pain Severity

 
single-question low back pain surveyMONDAY, Feb. 4 (HealthDay News) -- Patient-reported chronic low-back pain (CLBP) severity, based on answering a single question, provides an accurate indicator of patient-reported health status, according to a study published in the February issue of the Journal of Spinal Disorders & Techniques.

Alesia B. Sadosky, Ph.D., M.P.H., M.B.A., from Global Health Economics and Outcomes Research at Pfizer Inc. in New York City, and colleagues analyzed data from the 2009 Adelphi Disease Specific Programme, in which patients reported the severity of their CLBP condition by answering a single question: "Please rate how your CLBP condition is today." Patient reported severity (mild, moderate, or severe) was assessed with respect to scores on standard patient self-report measures of pain and function.

The researchers found that, of the 1,363 survey respondents (49 percent male; mean age, 54.8 years; 52 percent employed at least part time), 28.6, 53.3, and 18.2 percent, respectively, reported mild, moderate, and severe CLBP. As the severity of CLBP increased, there were significant differences observed in increased pain, pain interference with function, and CLBP-linked impairment while working, mainly due to presenteeism. There were higher costs related to lost work productivity resulting from increased work impairment, with estimated annual lost productivity costs of $7,080 per patient for mild CLBP, $16,616 for moderate CLBP, and $25,032 for severe CLBP. CLBP severity was inversely associated with patient satisfaction with pain-related medication.

"The association between patient-reported CLBP severity and other patient-reported outcomes demonstrates that in the clinical setting, patient-reported CLBP severity provides an accurate and suitable indicator of patient-reported health status," the authors write.

Several authors are employed by or disclosed financial ties to Pfizer and Adelphi. The study was supported by Pfizer.

Abstract
Full Text (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 
 

Further Reading
The US Food and Drug Administration has announced the approval of a new combination treatment for hepatitis C virus.
Half of US states are poorly prepared to prevent, detect, and respond to infectious disease outbreaks. That was the main conclusion of a report issued jointly by the Trust for America's Health and the Robert Wood Johnson Foundation.
Prostaglandin analogue eye drops significantly reduce the risk of vision loss in patients with glaucoma, according to a new study published online Dec. 18 in The Lancet.
More Reading